[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"King Faisal Specialist Hospital & Research Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":404},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,50,100,126,152,176,197,224,256,278,301,344,374],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635969","high-flow-tracheal-oxygen-for-weaning-of-tracheostomized-patients-100635969",false,"NCT07559591","High Flow Tracheal Oxygen for Weaning of Tracheostomized Patients","High Flow Tracheal Oxygen for Weaning of Tracheostomized Mechanically Ventilated Patients: A Pilot Randomised Controlled Trial (HFTO WEAN Trial)","HFTO-WEAN","Inclusion Criteria:\n\n1. Adults ≥ 18 years of age\n2. Intensive care unit (ICU) patients with tracheostomy inserted during the index ICU admission.\n3. Mechanically ventilated for ≤60 days.\n4. Successful spontaneous breathing trial for 1 hour.\n\nExclusion Criteria:\n\n1. Planned tracheostomy post head and neck surgery with ICU stay less than 48 hours\n2. Patient transferred from another hospital only if the intubation and tracheostomy dates are unavailable, otherwise would be eligible.\n3. Patient with an imminent plan for palliation and comfort care.\n4. Patient or substitute decision-maker declines consent to the study.\n5. The treating physician declines consent to the study.","ALL","18 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this pilot randomized controlled trial (RCT), the investigators aim to explore the feasibility of conducting a powered RCT that examines the efficacy and safety of high flow tracheal oxygen (HFTO) in weaning critically ill tracheostomy patients from mechanical ventilation.\n\nObjective of the study\n\n1. To assess the feasibility of conducting a larger RCT as primary objective.\n2. To explore the effect of using HFTO in mechanically ventilated tracheostomized critically ill patients on ventilator-free days (VFD) compared to standard of care method using tracheal mask (TM) as secondary objective.",[27,28,29],"Tracheostomized Patients","Mechanical Ventilation Weaning","High Flow Oxygen Therapy",[31,32,33,34,35,36],"tracheostomized patients","tracheostomy","mechanical ventilation weaning","high flow tracheal oxygen","mechanical ventilation liberation","critically ill","RECRUITING","2026-05-29",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":41},"2026-05-17",{"date":45,"type":21},"2027-05",{"name":47,"class":48},"King Faisal Specialist Hospital & Research Center","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":81,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":49},"100625999","saudi-emergency-laparotomy-audit-100625999","NCT07429929","Saudi Emergency Laparotomy Audit","Saudi Emergency Laparotomy Audit (SELA): A National Multicenter Observational Audit of Outcomes Following Emergency Laparotomy in Saudi Arabia","SELA","Inclusion Criteria:\n\n* Age ≥14 years\n* Undergoing an emergency (E1-E4) laparotomy, laparoscopy, or laparoscopically-assisted abdominal operation\n* Procedures involving the stomach, small bowel, large bowel, or rectum for acute pathology (e.g., perforation, ischemia, abscess, bleeding, or obstruction)\n* Washout\u002Fevacuation of intra-peritoneal abscess or hematoma (excluding those secondary to appendicitis or cholecystitis)\n* Bowel resection or repair for obstructed\u002Fincarcerated hernias with acute presentation (incisional, umbilical, inguinal, femoral)\n* Adhesiolysis (open or laparoscopic)\n* Trauma-related emergency abdominal procedures\n* Inoperable pathology where a definitive operative procedure was intended (not purely diagnostic)\n* Return to theatre for major wound dehiscence (\"burst abdomen\")\n* Complications requiring general surgical intervention following interventional radiology procedures\n* Complications requiring general surgical intervention following gynecological oncology surgery\n* Complications following elective or non-elective general\u002Fupper GI surgery, where the above criteria are met\n\nExclusion Criteria:\n\n* Age \\\u003C14 years\n* Elective laparotomy or laparoscopy\n* Diagnostic-only laparotomy or laparoscopy (unless abandoned due to inoperable disease)\n* Appendicectomy or cholecystectomy (including their complications), unless incidental to a more major non-elective gastrointestinal procedure\n* Non-elective hernia repair without bowel resection or adhesiolysis\n* Minor wound dehiscence repair (unless bowel resection is required)\n* Stoma formation via trephine or laparoscopic approach (include only if midline laparotomy is the primary procedure)\n* Vascular, obstetric, gynecological (except gynecological oncology complications requiring general surgery input), transplant, hepatobiliary, urological, renal, pancreatic, or splenic procedures","14 Years",{"count":60,"type":21},10000,"OBSERVATIONAL","The Saudi Emergency Laparotomy Audit (SELA) is a national, multicenter observational clinical audit designed to evaluate outcomes and quality of care for patients undergoing emergency laparotomy in Saudi Arabia. The audit will collect standardized data on patient characteristics, comorbidities, perioperative processes, and postoperative outcomes through a retrospective baseline phase followed by a prospective registry phase. SELA aims to establish national benchmarks, assess applicability of international risk models, support development of a Saudi-specific risk prediction tool, and drive quality improvement through systematic feedback and benchmarking across participating hospitals.",[64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80],"Laparotomy","Laparotomy Surgery","Emergency Treatment","Abdominal Diseases","Gastrointestinal Diseases","Intestinal Obstruction","Intestinal Obstruction and Ileus","Intestinal Perforation","Intestinal Ischemia","Peritonitis Infectious, Gastrointestinal Perforation, Surgical Infection, Postoperative Complications","Peritonitis Bacterial","Peritonitis Caused by Perforated Left-sided Colon Diverticulitis","Peritonitis Infectious","Sepsis","Postoperative Complications After Gastrointestinal Operations","Surgical Procedures, Operative","Mortality",[82,83,84,85,80,86,87,88,89,90],"Emergency laparotomy","Surgical audit","Postoperative outcomes","Perioperative care","Morbidity","Quality improvement","Risk stratification","Retrospective audit","Saudi Arabia","NOT_YET_RECRUITING","2026-02-22",{"date":94,"type":41},"2026-02-24",{"date":96,"type":21},"2026-06-01",{"date":98,"type":21},"2028-12-31",{"name":47,"class":48},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100620429","reducing-skin-side-effects-in-patients-receiving-radiation-on-tomotherapy-100620429","NCT07357506","Reducing Skin Side Effects in Patients Receiving Radiation on Tomotherapy","Mitigating Cutaneous Toxicity in Patients Undergoing TomoTherapy; A Randomized Controlled Trial of Skin-Protective Strategies","MCTPUT","Inclusion Criteria:\n\n* Patients aged 18 to 80 with newly diagnosed head and neck (H\\&N) carcinoma (confirmed by pathology)\n* Must be receiving radiotherapy using Tomotherapy\n\nExclusion Criteria:\n\n* Prior H\\&N radiotherapy\n* pre-existing skin disease\n* allergy to study products.","80 Years",{"count":110,"type":21},104,[24],"* Radiation dermatitis is a common side effect in head and neck cancer (HNC) patients receiving radiotherapy, especially with advanced techniques like TomoTherapy. The use of 6 MegaVoltage (MV) Flattening Filter-Free (FFF) beams and shorter Source to Skin Distance (SSD) in TomoTherapy may increase skin dose, leading to higher rates of skin reactions such as redness, irritation, and pain. These reactions can affect patient comfort, increase the risk of infection, and even interrupt treatment.\n* Although radiation dermatitis is frequent, there is no widely accepted standard for preventing or managing it. Supportive care programs, like the Dermatitis Control Program (DeCoP), and other supportive care programs using silicone-based semi-permeable barrier film have shown that simple measures-such as good skin hygiene and keeping the skin moist, can help reduce skin damage during treatment.\n* This study will evaluate the effectiveness of fragrance-free emollient (glycerol-based) + absorbent polyurethane foam dressing versus silicone-based semi-permeable barrier film dressing in preventing or reducing skin toxicity in HNC patients receiving TomoTherapy. These products are easy to apply, affordable, and widely available, making them practical options for routine care.",[114],"Head and Neck Cancer",[114,116,117],"Radiotherapy","Dermatitis","2026-01-21",{"date":120,"type":41},"2026-01-22",{"date":122,"type":21},"2026-02",{"date":124,"type":21},"2028-01",{"name":47,"class":48},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":49},"100620700","phase-1-cd19-chimeric-antigen-receptor-car-t-cells-in-adults-with-relapsedrefractory-cd19-positive-acute-lymphoblastic-leukemia-100620700","NCT07361029","CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed\u002FRefractory CD19 Positive Acute Lymphoblastic Leukemia","Phase Ia Study of a LentiGen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Patients With Relapsed\u002FRefractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) Using a Closed Transduction System","CD19 CART CELL","Inclusion Criteria:\n\n* Patients aged between 18 to 75 years old (patients is older than 18.0 and less than 75.0 years old) 2. Signed informed consent form 3. Ability to comply with the study protocol 4. Relapsed\u002Frefractory B-cell acute lymphoblastic leukemia (B-ALL):\n\n  1. Second or greater bone marrow (BM) relapse; or\n  2. Primary refractory, defined as not achieving complete remission (CR) after 2 cycles of a standard chemotherapy regimen, or Chemo-refractory, defined as not achieving CR after 1 cycle of standard chemotherapy for relapsed leukemia; or\n  3. Philadelphia chromosome-positive ALL intolerant of or with 2 failed lines of tyrosine kinase inhibitor (TKI) therapy; or\n  4. Relapsed patients ineligible for Allogeneic Stem Cell Transplant (AlloSCT) due to lack of a suitable donor.\n  5. Relapsed after AlloSCT. at least 12 weeks after alloSCT or relapse happened after withdrawing the post-transplant immunosuppression\n  6. Relapsed after prior CAR T cell and still CD19 positive. . (Patients with a history of ≥grade CRS, ≥ grade 3 ICANS, or severe hypersensitivity reactions following prior CAR T-cell therapy should be excluded.) 5. BM with ≥5% lymphoblasts by morphologic assessment at screening 6. For relapsed patients, documentation of CD19 tumor expression in BM or peripheral blood by flow cytometry or immunohistochemistry within 1 month of study entry 7. Patients with a history of CNS or meningeal involvement must be in a documented clinical remission prior to registration.\n\n     8\\. Alanine aminotransferase (ALT) ≤5 times the upper limit of normal for age 9. Bilirubin ≤2 x ULN 10. Patients with good renal function defined as Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 cc\u002Fmin.\n\n     11\\. Absolute Neutrophil Count (ANC): Patients must have an ANC ≥ 1.0 x 109\n\n     \u002FL without the use of growth factors 12. Platelet Count: Patients must have a platelet count ≥ 50 x 109\u002FL without transfusion support within 7 days of screening.\n\n     13\\. Absolute Lymphocyte Count: Patients must have an absolute lymphocyte count ≥ 0.5 x 109\u002FL.\n\n     14\\. Definition of Adequate Organ Function:\n     * Renal Function: Glomerular Filtration Rate (GFR) \\> 60mL\u002Fmin.\n     * Hepatic Function: AST\u002FALT ≤ 5 x ULN and bilirubin ≤ 2 x ULN. Total bilirubin 1.5 ULN (except Gilbert's syndrome).\n     * Pulmonary Function: Adequate respiratory function defined as oxygen saturation ≥ 93% on room air.\n     * Cardiac Function: Left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA scan and QTcF ≤ 480 ms. 15. Minimum level of pulmonary reserve defined as grade ≤1 dyspnea and pulse oxygenation \\>93% on room air 16. Left ventricular ejection fraction ≥45% confirmed by echocardiogram within 30 days of screening 17. Karnofsky ≥ 70% and \u002For ECOG 0-2 at the time of screening 18. Women of child bearing age should have negative serum pregnancy test within 7 days prior to enrollment 19. If sexually active:\n\n  \u003C!-- -->\n\n  1. Females should use effective birth control 1 month prior to screening until 12 months after CAR T cell infusion\n  2. Males to use condom for six months after infusion 20. Meet institutional criteria to undergo leukapheresis or have an acceptable, stored leukapheresis product\n\nExclusion Criteria:\n\n1. Clinically Active central nervous system (CNS) involvement by malignancy\n2. History or presence of uncontrolled underlying seizure disorder not related to B-ALL\n3. History of or active clinically significant cardiovascular dysfunction, including any of the following:\n\n   * History of stroke within 24 months prior to the CD19 CAR T cells infusion or with ongoing sequelae\n   * History of transient ischemic attack within 12 months prior to the CD19 CAR T cells infusion\n   * History of myocardial infarction within 36 months prior to the CD19 CAR T cells infusion\n   * Symptomatic congestive heart failure (NYHA class III\u002FIV), unstable angina pectoris, cardiac arrhythmia requiring therapy\n   * Uncontrolled arrhythmias, or history of or active ventricular arrhythmia requiring medication\n   * Active or history of coronary heart disease that remains symptomatic\n   * Active or history of unstable or stable angina\n   * Left ventricular ejection fraction (LVEF) \\\u003C 45% confirmed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) scan\n4. Creatinine clearance \\\u003C 60\n5. Concomitant genetic syndromes associated with Bone Marrow (BM) failure states, such as Fanconi anemia, Kostmann syndrome, Schwachman syndrome, or any other BM failure syndrome; patients with Down syndrome are not excluded\n6. Burkitt lymphoma\u002Fleukemia\n7. Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and no evidence of active disease\n8. Treatment with any prior gene therapy product (except prior CAR-T cell therapy)\n9. Positive HIV test within 8 weeks of screening\n10. Serologic status reflecting active hepatitis B or C infection: Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)\n11. Received an investigational medicinal product on trial within the 30 days prior to screening\n12. Pregnant\n13. Lactating\n14. Women of child-bearing potential and all male participants, unless using highly effective methods of contraception for 1 year after CAR-T infusion\n15. Therapeutic systemic doses of steroids (\\>=0.5mg\u002Fkg prednisone equivalent) must be stopped \\>72 hours prior to lymphodepletion\n16. TKIs and hydroxyurea must be stopped \\>72 hours prior to lymphodepletion\n17. The following drugs must be stopped \\>1 week prior to lymphodepleting chemotherapy:\n\n    vincristine, 6- mercaptopurine, 6-thioguanine, methotrexate 2 weeks prior to CART infusion: salvage chemotherapy (e.g., clofarabine, cytosine arabinoside \\>100 mg\u002Fm2\n\n    , anthracyclines, cyclophosphamide, methotrexate ≥25 mg\u002Fm2\n\n    ), excluding the required lymphodepleting chemotherapy drugs\n18. Pegylated asparaginase must be stopped \\>4 weeks prior to CAR T cell infusion\n19. CNS disease prophylaxis and\u002For intrathecal chemotherapy must be stopped \\>1 week prior to CAR T cell infusion\n20. Radiation therapy at non-CNS site must be completed \\>2 weeks prior to CAR T Cell infusion\n21. CNS-directed radiation must be completed \\>8 weeks prior to CAR T cell infusion\n22. Known History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study (including, but not limited to, cyclophosphamide and fludarabine used in the lymphodepleting chemotherapy, DMSO used as a cryoprotectant in the cell media, etc.)\n23. Autologous transplant within 6 weeks of planned CAR-T cell infusion\n24. Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy.\n25. Primary Immunodeficiency Patients:\n\n    • Patients with known primary immunodeficiency disorders are excluded due to increased risk of adverse outcomes.\n26. Recent Live Vaccine Administration:\n\n    * Patients who have received a live vaccine within 4 weeks prior to enrolment are excluded.\n    * Additionally, vaccination with live vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy","75 Years",{"count":136,"type":21},24,[138],"PHASE1","This is a Phase Ia, open label, dose finding single center trial designed to evaluate the maximum tolerated dose, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CD19 CAR T cells targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in adults (age 18 - 75) with relapsed\u002Frefractory acute lymphoblastic leukemia (ALL).",[141],"Relapsed Refractory Acute Lymphoblastic Leukemia",[143,144],"CD19 CAR T","relapsed\u002Frefractory acute lymphoblastic leukemia (ALL).","2026-01-14",{"date":120,"type":41},{"date":148,"type":41},"2025-07-29",{"date":150,"type":21},"2028-07",{"name":47,"class":48},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":49},"100617865","a-randomized-controlled-trial-on-the-effectiveness-of-early-versus-conservative-rehabilitation-following-rotator-cuff-repair-100617865","NCT07324174","A Randomized Controlled Trial on the Effectiveness of Early Versus Conservative Rehabilitation Following Rotator Cuff Repair","Inclusion Criteria:\n\n1. Adults aged 18 years and older\n2. Patients diagnosed with a symptomatic tear of the rotator cuff and listed for surgical repair\n3. Rotator cuff tear confirmed by MRI\n4. Patients screened by the surgeon as suitable to participate\n5. Able to attend out-patient follow-up physiotherapy appointment\n6. Demonstrate the ability and willingness to consent and continue participation in the study\n7. Able to understand Arabic or English Language\n\nExclusion Criteria:\n\nA patient will not be eligible for participation in the study if any of the following criteria apply:\n\n1. Individuals younger than 18 years\n2. Those unable or unwilling to consent or continue with the study.\n3. Moderate to severe arthritis seen on x rays or MRI\n4. Fatty infiltration grade \\>= 3","17 Years","100 Years",{"count":161,"type":21},86,[24],"Background Rotator cuff tears (RCTs) are a common, costly, and often persistent musculoskeletal complaint, with an increasing number of shoulder pain patients undergoing surgical repair each year. Whereas many asymptomatic RCTs can be successfully managed non-surgically, when conservative treatment fails, surgery is recommended. However, there is a lack of consensus on the best approach to postoperative rehabilitation, an important factor in the recovery process of rotator cuff repairs. This study aims to investigate the effectiveness of early versus delayed rehabilitation following rotator cuff repairs.\n\nObjective This study aims to determine the effectiveness of early versus delayed rehabilitation following rotator cuff repairs.\n\nMethod A two-armed, randomized controlled trial will be conducted in an outpatient physical rehabilitation department at a tertiary hospital. The sample will include 88 adults aged 18 years or older with RCTs. From the day after surgery, the intervention will engage in supervised passive range of motion (ROM) exercises, focusing on forward flexion and external rotation. They will receive daily exercise instructions, including table slides and active movements for the elbow, wrist, and hand, while also practicing passive shoulder flexion and abduction based on their pain limits. Participants are encouraged to do gentle pendulum exercises and passive movements three times daily to improve shoulder mobility. Active shoulder exercises will be restricted until six weeks post-surgery to ensure healing. Sling use will decrease by the sixth week, allowing for active ROM exercises to start. Participants in the control group will follow a delayed rehabilitation protocol, learning strict sling immobilization techniques for the first six weeks postoperatively. During this period, sling removal will be allowed only for basic exercises and daily activities, with no other shoulder movements encouraged initially. Sling use will end by the sixth week, followed by the start of active ROM exercises.\n\nOutcome measures will include shoulder ROM, muscle power, a numeric pain scale (NPS), shoulder pain disability index (SPADI), and EQ-5D-5L questionnaires assessed at 3, 6, and 12 months follow-up between the two groups. Rotator cuff integrity will be evaluated using MRI at baseline and at 12 months post-surgery.\n\nConclusion We anticipate that this study will add to the body of knowledge required to make effective treatment choices on the management of patients following rotator cuff repairs. Ultimately, this trial aims not only to influence national rehabilitation guidelines but also to enrich the global evidence base concerning optimal rehabilitation strategies following rotator cuff repair, especially for populations in the Middle East and Gulf regions.",[165],"Rotator Cuff Tear",[167],"Rotator cuff tear, post rotator cuff repair, physical rehabilitation, early rehabilitation, delayed rehabilitation","2026-01-07",{"date":170,"type":41},"2026-01-09",{"date":172,"type":21},"2026-01-01",{"date":174,"type":21},"2029-12-30",{"name":47,"class":48},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":186,"studyType":61,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100617296","saudi-cabg-audit-and-registry-100617296","NCT07316777","Saudi CABG Audit and Registry","Protocol for Development and Implementation of the Saudi CABG Audit and Registry: A Prospective National Clinical Registry","SCAR","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Undergoing isolated CABG\n* Undergoing CABG with concomitant procedures (e.g., valve repair or replacement)\n* Undergoing on-pump, off-pump, minimally invasive, or robotic CABG\n* Procedures performed electively, urgently, or emergently\n\nExclusion Criteria:\n\n* Redo CABG when the primary operative record is not available\n* Patients younger than 18 years",{"count":185,"type":21},3000,"12 Months","The Saudi CABG Audit and Registry (SCAR) is a prospective, multicenter national clinical quality registry designed to systematically collect perioperative and long-term outcome data for all patients undergoing coronary artery bypass grafting (CABG) in Saudi Arabia. The registry will begin with a pilot phase in selected tertiary cardiac centers and will progressively expand to national coverage. SCAR captures detailed information on patient demographics, cardiac status, operative techniques, postoperative outcomes, and 1-year follow-up, including patient-reported quality-of-life measures (EQ-5D and SF-36). The aim is to establish a standardized national platform for benchmarking, quality improvement, and real-world evidence generation to support clinical decision-making and health policy development in cardiac surgery. Data are collected prospectively through secure electronic systems, anonymized before central storage, and analyzed using standardized definitions aligned with international registries such as STS and E-CABG.",[189],"Coronary Artery Bypass Graft (CABG)","2025-12-18",{"date":192,"type":41},"2026-01-05",{"date":172,"type":21},{"date":195,"type":21},"2027-12-31",{"name":47,"class":48},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":49},"100617434","ai-assisted-skin-assessment-for-pressure-injury-prevention-in-critical-care-nurses-100617434","NCT07318571","AI-Assisted Skin Assessment for Pressure Injury Prevention in Critical Care Nurses","A Randomized Controlled Trial on the Application of Artificial Intelligence (AI) in Skin Assessment for Pressure Injury Prevention and Staging by Critical Care Nurses","IT-PIP","Inclusion criteria\n\n* Nurses working within the organisation for at least 6 months\n* Nurses involved in direct patient care for over 50% of their work time.\n* Skin assessments and staging for patients at risk for developing pressure injuries (Using the Braden Scoring system).\n* Adult Patients (18 years and older)\n* Patients who are currently admitted to the ICU and are receiving critical care treatment.\n* No current severe skin conditions patients without active severe dermatological conditions (e.g., large open wounds, severe rashes) that would interfere with the AI-based skin assessment process.\n\nExclusion criteria\n\n* Nurses working within the organization for less than 6 months\n* Nurses involved in direct patient care for less than 50% of their work time\n* End-of-Life Care or Terminal Illness- patients receiving end-of-life care or those with a terminal diagnosis, where the prevention of pressure injuries may not be a priority and where participation in the study may not align with their care goals.\n* Severe or active dermatological conditions- patients with active skin conditions such as severe rashes, burns, or other dermatological issues that could interfere with accurate skin assessments by AI or confound the study results.\n* Recent Skin Grafts or Advanced Wound Care- patients who have recently undergone skin grafts or those receiving complex wound care treatments that are outside the scope of typical pressure injury prevention practices.\n* Inability to Maintain Required Positioning for Skin Assessment- patients who are physically unable to remain in the necessary position for the skin assessments, either due to severe mobility restrictions or critical medical conditions.",{"count":206,"type":21},90,[24],"The goal of this clinical trial is to learn whether an artificial intelligence (AI)-assisted skin assessment tool can improve the accuracy of pressure-injury staging in critical-care nurses. The study also aims to understand whether the AI tool increases nurses' knowledge and confidence in performing skin assessments. The main questions it aims to answer are:\n\nDoes AI-assisted assessment improve the accuracy of pressure-injury staging compared with standard visual assessment?\n\nDoes the use of AI improve nurses' knowledge and confidence related to skin assessment and pressure-injury staging?\n\nResearchers will compare nurses who use an AI-assisted mobile application with nurses who perform standard manual assessments to see whether the AI tool improves staging accuracy and supports early identification of pressure injuries.\n\nParticipants will:\n\nComplete brief questionnaires about their knowledge and confidence before and after training\n\nPerform skin assessments on their assigned ICU patients using either standard methods or the AI tool.\n\nHave their assessments compared with those of a blinded wound-care specialist, who will determine the most accurate staging",[210],"The Study Focuses on Skin Assessment and PI Staging in ICU Patients",[212,213,214,215,216],"Artificial intelligence","critical care","intensive care","nurses","Pressure injuries",{"date":218,"type":41},"2026-01-06",{"date":220,"type":41},"2025-11-24",{"date":222,"type":21},"2026-05-16",{"name":47,"class":48},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":234,"conditions":235,"keywords":239,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":49},"100611627","code-status-discussions-in-muslim-icu-patients-insights-into-physician-family-communication-100611627","NCT07243041","Code Status Discussions in Muslim ICU Patients: Insights Into Physician-Family Communication","A Prospective Study Exploring Factors Affecting ICU Transitions and Handling of Code Status - Insights Into Physician and Family Communication in a Muslim Patient Population","FAITH-ICU","Inclusion Criteria:\n\n* ICU physicians (residents, fellows, assistant consultants, or consultants) involved in direct patient care\n* ICU physicians who conduct code status or Do Not Attempt Resuscitation (DNAR) discussions with patients' families during ICU admission\n* Willingness of ICU physicians to participate voluntarily by completing a post-goals-of-care discussion questionnaire\n* Adult patients (≥18 years) admitted to the ICU during the study period for whom a code status discussion occurred\n\nExclusion Criteria:\n\n* ICU physicians who decline participation\n* Code status discussions involving patients younger than 18 years of age\n* Discussions in which the physician was not directly involved",{"count":233,"type":21},320,"This observational study aims to explore the real-time experiences, perceptions, and challenges faced by intensive care unit (ICU) physicians during goals-of-care discussions-specifically Do Not Attempt Resuscitation (DNAR) and end-of-life decision-making conversations-with families of critically ill patients in a Muslim-majority healthcare setting.\n\nThe study seeks to identify factors that influence whether a DNAR decision is reached after physician-family discussions, and how physician experience, family dynamics, religious perspectives, and institutional support affect communication outcomes and care transitions.\n\nParticipants will include ICU physicians (residents, fellows, and consultants) who routinely conduct DNAR discussions as part of clinical care. After each discussion, physicians will complete a brief structured questionnaire about their perceptions of the interaction, family emotions, and decision outcomes. These responses will be anonymously linked to limited, de-identified patient-level data (e.g., diagnosis, ICU course, and outcome) extracted retrospectively from the electronic medical record.\n\nNo patients or family members will be contacted directly. Data collection will occur prospectively over two years at King Faisal Specialist Hospital \\& Research Centre-Jeddah.\n\nFindings from this study are expected to provide culturally grounded insights that inform physician training, enhance family-centered communication, and guide policy development for DNAR and end-of-life discussions in Muslim-majority intensive care units.",[236,237,238],"End of Life Care","Muslim","Decision Making ,Shared",[240,241,242,243,244,245,246,247],"goals of care","do not attempt resuscitation","ICU","Shared Decision-Making","Family Communication","Muslim Healthcare Context","Cultural Factors","palliative care","2025-12-14",{"date":250,"type":41},"2025-12-19",{"date":252,"type":41},"2025-11-01",{"date":254,"type":21},"2027-10-31",{"name":47,"class":48},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":4},"100597253","comparing-blood-glucose-control-intraoperative-between-insulin-drip-vs-insulin-boluses-will-provide-valuable-information-on-the-optimal-method-for-achieving-blood-glucose-control-intraoperatively-100597253","NCT07056088","Comparing Blood Glucose Control Intraoperative Between Insulin Drip vs. Insulin Boluses Will Provide Valuable Information on the Optimal Method for Achieving Blood Glucose Control Intraoperatively.","A Randomized Controlled Trial Comparing Blood Glucose Control Intraoperative Between Insulin Drip vs. Insulin Boluses","RANDOM-IB","Inclusion Criteria:\n\n* All adult patients (above 18 y of age undergoing Cardiac surgery with preoperative blood glucose level (80 -180 mg\u002FdL)\n* Patient with History of diabetes and those taking antidiabetics medications.\n\nExclusion Criteria:\n\n* Patients with known allergy or insulin intolerance.\n* Patients with severe hepatic Dysfunction.\n* Patient with History of hypoglycemic events in the past 6 month prior to surgery.",{"count":265,"type":21},384,[24],"Cardiac surgery patients often experience elevated blood glucose levels, which can lead to poor surgical outcomes and increased postoperative complications. Therefore, tight blood glucose control during surgery is important. Currently, there is no consensus on the best method for blood glucose control during cardiac surgery. This proposal aims to perform a randomized controlled trial to compare blood glucose control intraoperatively using an insulin drip versus insulin boluses. The primary objective of the study is to compare blood glucose control intraoperatively between patients who receive insulin drip and patients who receive insulin boluses during adult cardiac surgery. This study will be a randomized controlled trial in which adult patients undergoing cardiac surgery will be randomized into two groups: insulin drip and insulin boluses. Patients with a history of diabetes or those currently taking antidiabetic medications will be included in the study. This randomized controlled trial will provide valuable information on the optimal method for achieving blood glucose control intraoperatively. The results of this study may help improve patient outcomes and reduce the incidence of postoperative complications.",[269],"Hypoglycemia (Diabetic)","2025-07-03",{"date":272,"type":41},"2025-07-09",{"date":274,"type":21},"2025-07",{"date":276,"type":21},"2029-08",{"name":47,"class":48},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100592464","the-predictability-of-cd19-expression-across-primitive-cellular-fractions-of-relapsed-b-all-on-outcomes-of-cd19-targeted-car-t-cells-100592464","NCT06993766","The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells","Inclusion Criteria:\n\nAll patients (adults and pediatrics) with confirmed diagnosis with B-ALL and receipt CD19-targeted CAR-T cell therapy and have diagnostic or post -treatment BM or PB samples processed with a standard B-ALL immunophenotyping panel. with the presence of CD45, CD19, CD34, and CD38 in the antibody panel.",{"count":285,"type":21},100,"Acute lymphoblastic leukemia (ALL) is a malignant proliferation of immature lymphoid cells within the bone marrow, blood, and extramedullary sites. According to the SEER Cancer Statistics Review, the incidence was estimated to be at around 1·6 per 100000 people in 2014, with around 6000 new cases diagnosed in 2018. This disease is more frequent in children aged 1-4 years, then drops reaching the lowermost point between 25 years and 45 years. Generally, around 60% of ALL cases are diagnosed before the age of 20 years. Despite significant improvements in 5-year overall survival reaching around 90% in children, only 25% of patients older than 50 years old were alive 5 years after diagnosis1,2. These survival figures are much worse when dealing with relapsed disease. Cases of relapsed or refractory ALL are usually offered allogeneic stem cell transplantation that can establish meaningful disease control after achieving the best disease control depicted in lack of measurable residual disease3. However, the inability of performing allogeneic stem cell transplantation in some patients, especially elderly patients, represents unmet needs for advancing treatment for these challenging ALL cases.\n\nCellular immunotherapy with CD19-directed chimeric antigen receptor (CAR) T-cells has demonstrated encouraging results for the treatment of B-cell ALL (B-ALL). Currently used CAR T-cells are genetically engineered autologous T cells that express the antigen-binding domain linked to a costimulatory molecule and an intracellular T-cell receptor signaling domain. CAR T-cells function in a major histocompatibility complex-independent manner. Because of its expression on nearly all B-ALL, CD19 became the most sensible target. This paved the way for using tisagenlecleucel and brexucabtagene autoleucel in patients with B-ALL with astonishing outcomes4-6. However, the dependence on expression of the antigen of target can be an \"Achilles' heel\" for CAR T-cells similar to monoclonal antibodies, and loss of this target is a major escape mechanism by which cancer cells can evade immunotherapy. Mechanisms of antigenic loss may include genetic modulations, epitope masking, or a cell lineage switch with secondary loss of the target epitope7.\n\nCell plasticity is the ability of cells to be reprogrammed and to alter their fate and identity, which can enable homeostasis and restoration following injury. Pathological plasticity allows cancer cells to acquire new phenotypic and\u002For functional features leading to disease progression and resistance to therapy8. One of the most studied and established phenotypic and functional plasticity is KMT2A-r ALL9. The seminal work of Dr. John Dick and his lab in establishing the concept of leukemia stem cell was instrumental to the field. Transplantation of human ALL into NOD\u002FSCID mice generates a disease in these mice that is reminiscent of the human disease10. The attributes of self-renewal and clonogenic proliferation are considered \"functional\" markers for stemness of these leukemia initiating cells. Because some of these functional assays are laborious, multiple efforts have been exerted to uncover the most accurate markers to label these cells that cab reliably predict this unique cellular population. In addition to cell-intrinsic factors for plasticity that are mentioned above, cell-extrinsic or \"niche\" elements can fuel cellular plasticity when they occur. Despite these limitations, CD34+CD38- cell fraction is most likely to harbor the most primitive and quiescent cells that can fuel disease existence11.\n\nKing Faisal Specialist Hospital and Research Center is one of the leading hospital in the region in providing novel CAR T-cell therapy for management of challenging cases of relapsed and or refractory B-ALL, and has delivered a large number of products given its excellence reputation and the large number of cases treated at the center. We aim through our study to analyze the correlation between CD19 expression across the realm of B-ALL hierarchy using samples from relapsed B-ALL patients who underwent CAR T-cells therapy at our center and weigh this against their outcomes in relation to the percent expression of CD19 at each cellular faction: CD34+CD38-, CD34+CD38+, and CD34-CD38+.",[288,289,290],"Relapsed B-ALL","CAR T-cells","CD19-directed CAR T-cell Therapy",[292],"CAR T-cell","2025-05-19",{"date":295,"type":41},"2025-05-29",{"date":297,"type":21},"2025-05-20",{"date":299,"type":21},"2030-05-31",{"name":47,"class":48},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":49},"100590970","phase-4-octreotide-vs-splenic-artery-ligation-for-portal-flow-modulation-in-living-donor-liver-transplants-scalop-trial-100590970","NCT06974344","Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)","Randomized Controlled Trial Protocol Comparing Splenic Artery Ligation Versus Octreotide for Portal Flow Modulation (SCALOP) in Living Donor Liver Transplantation","SCALOP","Inclusion Criteria:\n\n1. Age ≥ 18 and \\\u003C70 years\n2. Male and female genders\n3. Undergoing Living Donor Liver Transplant (LDLT)\n4. All indications\n5. Receiving a small-for-size graft requiring portal flow modulation\n6. Informed consent provided.\n\nExclusion Criteria:\n\n1. Deceased Donor Liver Transplantation (DDLT)\n2. Dual LDLT or dual LDLT\u002FDDLT\n3. Pregnancy\n4. Known allergy to Octreotide \u002F Somatostatin analogue","70 Years",{"count":311,"type":21},80,[313],"PHASE4","The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are:\n\n* Is octreotide (a medication) as effective or better than splenic artery ligation (surgery) in reducing complications after transplantation?\n* Which treatment better controls blood flow while causing fewer side effects?\n\nResearchers will compare octreotide (given through an IV) to splenic artery ligation (performed during surgery) to see which approach works best for patients receiving small liver grafts.\n\nParticipants will:\n\n* Be randomly assigned to receive either octreotide or splenic artery ligation during their transplant surgery\n* Have their liver blood flow monitored closely during and after surgery\n\nBe followed for 90 days and 1 year to track complications, hospital stay, recovery, and survival.\n\nThis study may help doctors choose safer, more effective treatments for patients needing small liver grafts.",[316],"Small-for-Size Syndrome",[318,319,320,321,322,323,324,325,326,327,328,329,330,331,80,332,333,316,334,335],"Living Donor Liver Transplantation","LDLT","Small-for-Size Graft","SFS","Portal Flow Modulation","Graft Inflow Modulation","Octreotide","Somatostatin Analogue","Splenic Artery Ligation,","SAL","Randomized Controlled Trial","RCT","Complications","Outcomes","Liver Hemodynamics","Early Allograft Dysfunction","SFSS","Survival","2025-05-08",{"date":338,"type":41},"2025-05-15",{"date":340,"type":21},"2025-06-01",{"date":342,"type":21},"2030-09-01",{"name":47,"class":48},{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":49},"100386629","phase-3-comparing-post-transplant-cyclophosphamide-as-gvhd-prophylaxis-to-standard-of-care-for-acute-leukemia-patients-100386629","NCT04314219","Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients","Comparing Post-Transplant Cyclophosphamide with Calcineurin Inhibitors As a GVHD Prophylaxis to Standard Care of Methotrexate and Calcineurin Inhibitors for Acute Leukemia Incorporating Patient Pharmacogenomics Profiling","PTCy-PMAT","Inclusion Criteria:\n\n* Patients with Acute Leukemias (AML, ALL) in morphologic complete remission with or without hematologic recovery\n* Patients must have a fully matched (8\u002F8) related donor willing to donate peripheral blood stem cells and must meet institutional criteria for donation\n* Planned Myeloablative conditioning regimen\n* Cardiac function: ejection fraction at rest ≥ 50% by MUGA or TTE\n* Estimated creatinine clearance greater than 50 mL\u002Fminute\n* Pulmonary function: DLCO ≥ 50% (adjusted for hemoglobin), and FVC and FEV1 ≥ 50%\n* Liver function: total bilirubin \\\u003C 2x the upper limit of normal (unless elevated bilirubin is attributed to Gilbert's Syndrome) and ALT\u002FAST \\\u003C 2.5x the upper normal limit\n* Signed informed consent\n\nExclusion Criteria:\n\n* Karnofsky or Lansky Performance Score \\\u003C 70%.\n* Active disease\n* Patients with uncontrolled bacterial, viral, or fungal infections\n* Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated\n* Patients seropositive for HIV-1 or -2\n* Patients seropositive for HTLV-I or -II\n* Patients with active Hepatitis B or C viral replication by PCR\n* Women who are pregnant (positive serum or urine βHCG) or breastfeeding\n* Females with childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use effective forms of birth control or abstinence for one year after transplantation\n* History of uncontrolled autoimmune disease or on active treatment\n* Patients with prior malignancies, except resected non-melanoma skin cancer or treated cervical carcinoma in situ; cancer treated with curative intent ≥ 5 years previously will be allowed; cancer treated with curative intent \\\u003C 5 years previously will not be allowed.","65 Years",{"count":354,"type":21},264,[356],"PHASE3","This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate\u002Fcalcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors for their efficacy as a new GVHD prophylaxis strategy.",[359,360],"Acute Lymphoblastic Leukemia (ALL) in Complete Remission","Acute Myeloid Leukemia (AML) in Remission",[362,363,364,365],"Sibling Donor Transplant","Allogeneic hematopoietic cell transplantation","GvHD Prophylaxis","Myeloablative regimen","2025-03-12",{"date":368,"type":41},"2025-03-13",{"date":370,"type":41},"2021-08-15",{"date":372,"type":21},"2026-12",{"name":47,"class":48},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":381,"conditions":382,"keywords":390,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":4},"100567897","the-impact-of-type-2-diabetes-mellitus-on-cardiovascular-events-in-saudi-arabia-now-and-future-100567897","NCT06674161","The Impact of Type 2 Diabetes Mellitus on Cardiovascular Events in Saudi Arabia Now and Future","Inclusion Criteria:\n\nAll adult patients with available records in the western region of Saudi Arabia\n\nExclusion Criteria:\n\nage below 18 years",{"count":311,"type":21},"Cardiovascular disease (CVD) and Type 2 diabetes mellitus (T2DM) are major global health challenges with significant morbidity and mortality. In Saudi Arabia, the prevalence of CVD and T2DM is increasing. This poses a significant burden on the healthcare system. Despite extensive global research, there remains a lack of comprehensive studies examining the combined impact of CVD and T2DM in the Saudi population, particularly in the Western region. Objectives: The primary objectives of the study are: (1) quantify the incidence and mortality rates of CVD and T2DM across various demographics in the Western region of Saudi Arabia; (2) analyse the demographic, clinical, and lifestyle factors contributing to cardiovascular risk in individuals with both conditions; (3) understand the influence of cultural, social, and religious beliefs on health behaviours related to CVD and T2DM using social media and survey data; (4) develop a predictive model for forecasting future cardiovascular events in the Saudi population; and (5) evaluate the impact of the ICD11 classification of CVD. Methodology: The project will include team of experts from King Faisal Specialist Hospital and Research Centre, Madinah, Taibah University, Islamic University of Madinah, University of Prince Mugrin, and King's College University, London. We will work under four workstreams (WS) which are: WS 1: This group will supervise the data collection, analysis and ensure efficient running of the project. WS 2: In year 1, retrospective data will be collected on the service needs, long term outcomes, and mortality of patients with CVD and T2DM, CVD only, T2DM only, and neither. Between Year 1 to 5, we will collect data prospectively using the new ICD-11 criteria. Both, retrospective and prospective data will be used to develop an artificial intelligence (AI) based predictive model. WS 3: Social media survey will be undertaken to understand health beliefs and behaviours influencing health related outcome to CVD and T2DM. WS 4: Undertake economic analyses into long-term resource utilisation and cost of care for CVD and T2DM.\n\nExpected Outcomes:\n\nThe study is expected to provide a detailed incidence and all-cause mortality CVD and T2DM in the Western region of Saudi Arabia. This will help in identifying risk factors and predictive for CVD and understand health beliefs and behaviours in Saudi Arabia. The data will help in developing policies, guidelines and awareness programmes in collaboration with policy makers. In conclusion, this study will impact by improving epidemiological knowledge and understanding of CVD and T2DM in Saudi Arabia. The project will support the overall mission of Saudi Vision 2030 with regard to increasing the health and well-being of the population.",[383,384,385,386,387,388,389],"Mortality of Patients with CVD","Mortality of Patients with CVD and T2DM","Mortality of Patients with T2DM","Mortality of Patients with Neither","Morbidity of CVD","Cardiovascular Diseases","Cardiovascular Diseases Risk",[391,392,393,394,395],"CVD","T2DM","mortality","morbidity","CVD risk","2024-11-02",{"date":398,"type":41},"2024-11-05",{"date":400,"type":21},"2024-11-30",{"date":402,"type":21},"2030-12-31",{"name":47,"class":48},""]